29 related articles for article (PubMed ID: 38596432)
1. The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities.
Zhang X; Joseph S; Wu D; Bowser JL; Vaziri C
bioRxiv; 2023 Nov; ():. PubMed ID: 38045328
[TBL] [Abstract][Full Text] [Related]
2. Use of mutation profiles to refine the classification of endometrial carcinomas.
McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations.
Jiang Y; Malouf GG; Zhang J; Zheng X; Chen Y; Thompson EJ; Weinstein JN; Yuan Y; Spano JP; Broaddus R; Tannir NM; Khayat D; Lu KH; Su X
Oncotarget; 2015 Nov; 6(37):39865-76. PubMed ID: 26431491
[TBL] [Abstract][Full Text] [Related]
4. FIGO staging of endometrial cancer: 2023.
Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
J Gynecol Oncol; 2023 Sep; 34(5):e85. PubMed ID: 37593813
[TBL] [Abstract][Full Text] [Related]
5. FIGO staging of endometrial cancer: 2023.
Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
Int J Gynaecol Obstet; 2023 Aug; 162(2):383-394. PubMed ID: 37337978
[TBL] [Abstract][Full Text] [Related]
6. The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities.
Zhang X; Joseph S; Wu D; Bowser JL; Vaziri C
NAR Cancer; 2024 Jun; 6(2):zcae015. PubMed ID: 38596432
[TBL] [Abstract][Full Text] [Related]
7. The emerging genomic landscape of endometrial cancer.
Le Gallo M; Bell DW
Clin Chem; 2014 Jan; 60(1):98-110. PubMed ID: 24170611
[TBL] [Abstract][Full Text] [Related]
8. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Basourakos SP; Li L; Aparicio AM; Corn PG; Kim J; Thompson TC
Curr Med Chem; 2017; 24(15):1586-1606. PubMed ID: 27978798
[TBL] [Abstract][Full Text] [Related]
9. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
10. Molecular carcinogenesis of endometrial cancer.
Liu FS
Taiwan J Obstet Gynecol; 2007 Mar; 46(1):26-32. PubMed ID: 17389185
[TBL] [Abstract][Full Text] [Related]
11. DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities.
Ovejero-Sánchez M; González-Sarmiento R; Herrero AB
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672401
[TBL] [Abstract][Full Text] [Related]
12. Molecular Genetics of Endometrial Carcinoma.
Bell DW; Ellenson LH
Annu Rev Pathol; 2019 Jan; 14():339-367. PubMed ID: 30332563
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
